Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 2/20 | 0.62 |
| ▸ | PRKCA | P17252 | 3/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.59 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115586 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| Propylene Glycol Monostearate SCHEMBL4429462 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL141668 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL1730481 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL29649070 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL180498 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL26974 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| Propylene Glycol Monostearate SCHEMBL35521 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL16458 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL1173237 | 1.00 | MAPT (1.00) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | claimed |
| CN-117224420-B | Oil-soluble lip-rounding compound peptide and preparation method thereof | 南京斯拜科生物科技股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-115955959-A | Nanostructured lipid carrier delivery systems, compositions, and methods | 康普萨姆公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230094753-A1 | NANOSTRUCTURE LIPID CARRIER DELIVERY SYSTEM, COMPOSITION, AND METHODS | CAPCIUM INC. (CA) | 2023-03-30 | — | — | US | claimed |
| CN-111432805-B | Pharmaceutical formulations of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime | 梅克里内科尼蒂翁公司 | 2023-02-17 | — | — | CN | claimed |
| EP-4110294-A1 | NANOSTRUCTURE LIPID CARRIER DELIVERY SYSTEM, COMPOSITION, AND METHODS | Capcium Inc. (CA) | 2023-01-04 | — | — | EP | claimed |
| CN-115006269-A | Washing-discharging two-in-one composition and application thereof | 凡可化妆品研究开发(广州)有限公司 | 2022-09-06 | — | — | CN | claimed |
| US-11123351-B2 | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | UMECRINE COGNITION AB (SE) | 2021-09-21 | — | — | US | claimed |
| EP-3716954-A1 | PHARMACEUTICAL FORMULATION OF 3 -ETHYNYL-3 -HYDROXYANDROSTAN-17-ONE OXIME | Umecrine Cognition AB (SE) | 2020-10-07 | — | — | EP | claimed |
| US-20200297737-A1 | PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME | UMECRINE COGNITION AB (SE) | 2020-09-24 | — | — | US | claimed |
| EP-1673062-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2014-03-12 | — | — | EP | claimed |
| US-20130165875-A1 | TRANSDERMAL ABSORPTION PREPARATION | ICURE PHARMACEUTICAL INC. (KR) | 2013-06-27 | — | — | US | claimed |
| EP-2561865-A2 | TRANSDERMAL ABSORPTION PREPARATION | Icure Pharmaceutical Inc. (KR) | 2013-02-27 | — | — | EP | claimed |
| CN-101170985-A | Hardenable antimicrobial dental compositions and methods | 3M INNOVATIVE PROPERTIES CO (US) | 2008-04-30 | — | — | CN | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | claimed |
| EP-1117380-A1 | GLUCOSIDE PAUCILAMELLAR VESICLES | Igen, Inc. (US) | 2001-07-25 | — | — | EP | claimed |
| US-6251425-B1 | Glucoside paucilamellar vesicles | IGEN, INC. | 2001-06-26 | — | — | US | claimed |
| WO-2000019980-A1 | GLUCOSIDE PAUCILAMELLAR VESICLES | IGEN, INC. (US) | 2000-04-13 | — | — | WO | claimed |
| EP-0461630-B1 | Production process of microspheres | EISAI CO LTD (JP) | 1995-09-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297737-A1 | PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME | HSD3B1, HSD3B2, HSD17B1 | MAPT 2567/4885LMNA 2065/4885KDM4E 2303/4885 |
| US-11123351-B2 | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | HSD3B1, HSD3B2, HSD17B1 | MAPT 2567/4885LMNA 2065/4885KDM4E 2303/4885 |
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | MAPT 829/4885LMNA 3268/4885KDM4E 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.